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Summary 
In this study, we describe a novel murine model of chronic intestinal inflammation induced by 
the hapten reagent 2,4,6-trinitrobenzene sulfonic acid (TNBS). Rectal application of low doses 
of TNBS in BALB/c and SjL/j mice resulted in a chronic transmural colitis with severe diar- 
rhea, weight loss, and rectal prolapse, an illness that mimics some characteristics of Crohn's dis- 
ease  in  humans.  The  colon of TNBS-treated  mice  on  day 7  was  marked by infiltration  of 
CD4 + T  cells; furthermore, in situ polymerase chain reaction studies revealed high levels of in- 
terferon (IFN)-~/mRNA in diseased colons.  Isolated lamina propria (LP)  CD4 + T  cells  from 
TNBS-treated mice stimulated with anti-CD3 and anti-CD28 antibodies exhibited a Thl pat- 
tern of cytokine secretion: a 20-50-fold increase in IL-2 and IFN-~/levels and a 5-fold decrease 
in IL-4 levels as compared with those of stimulated LP CD4 + T  cells  from control BALB/c 
mice.  Administration  of monoclonal anti-IL-12 antibodies  to  the  TNBS-treated mice both 
early (at 5 d)  and late (at 20 d) after induction of colitis led to a striking improvement in both 
the clinical and histopathological aspects of the disease and frequently abrogated the established 
colitis completely. Furthermore, LP CD4 + T  cells isolated from anti-IL-12-treated mice failed 
to secrete IFN-~/upon in vitro stimulation. In summary, the data demonstrate the pivotal role 
of IL-12 and  IFN-~/ in  a TNBS-induced  murine  model of chronic  intestinal  inflammation. 
Furthermore,  they  suggest  the  potential  utility  of anti-IL-12  antibodies  in  patients  with 
Crohn's disease. 
I 
nflammatory bowel disease (IBD) 1, encompassing Crohn's 
disease (CD) and ulcerative colitis, are idiopathic chronic 
diseases  occurring  with  increasing  frequency  in  Western 
populations  (1,  2).  RecentIy,  various  animal  models  of 
chronic intestinal inflammation have been estabhshed, which 
will  likely provide  new  insights  into  the  pathogenesis  of 
IBD (reviewed in 3). These include rats carrying transgenes 
of HLA-B27 and 132-microglobulin (4) and mice in which 
the genes for IL-2 (5),  IL-10 (6),  and the a  or 13 chain of 
the TCR (7) have been inactivated by homologous recom- 
bination.  In addition,  a colitis model has been recently es- 
tablished by the adoptive transfer of normal CD45RB hi T 
cells from BALB/c mice to C.B.-17  scid mice (8).  In this 
case,  the  transferred T  cells  manifest  a  Thl  cytokine  re- 
sponse  associated  with  granulomatous  inflammation  that 
can be abrogated by systemic treatment with  rIL-10, but 
not with rIL-4 (8). 
IL-12 is  a  recendy characterized  cytokine with  unique 
structure  and pleiotropic effects (9-12).  It consists of two 
disulfide-linked subunits, p40 and p35, that form function- 
ally  active  p40/p35  heterodimers  or  inhibitory  p40  ho- 
1Abbreviations used in this paper: CD, Crohn's disease; HPF, high power 
field; IBD, inflammatory  bowel disease; LP, lamina propia; TNBS, 2,4,6- 
trinitrobenzene sulfonic acid. 
modimers.  IL-12  is  produced  mainly  by  macrophages/ 
monocytes and  can be efficiently induced  by intracellular 
parasites, bacteria, and bacterial products. Functional stud- 
ies  showed  that  IL-12  enhances  cytolytic  activity of NK 
cells  and  macrophages,  and  that  it induces,  in  synergism 
with  the  B7/CD28  interaction,  cytokine production  and 
proliferation of activated NK cells  and T  cells  (13).  Fur- 
thermore, IL-12 plays a pivotal role in Thl T  cell differen- 
tiation, and it induces naive T  cells to produce IFN-~/. As a 
result  of this  ability to  drive  T  cell responses  to  the  Thl 
phenotype, IL-12 has been shown to be an effective treat- 
ment of established parasitic infections in mice (14,  15) that 
elicit a Th2 T  cell response.  In addition,  antibodies to IL- 
12 have been shown to prevent experimental autoimmune 
encephalitis, a disease mediated by Thl  T  cells (16).  In the 
present study, we describe a novel murine model of chro- 
nic  intestinal  inflammation by a  single  application  of the 
hapten reagent 2,4,6-trinitrobenzene sulfonic acid (TNBS). 
Furthermore,  we demonstrate that successful treatment of 
established colitis can be achieved by systemic administra- 
tion of antibodies to IL-12. Since the lamina propria (LP) T 
cell responses induced  by TNBS  show similarity to those 
observed in human CD, the data suggest the potential ther- 
apeutic use ofanti-IL-12 antibodies in this disease. 
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Induction  of Colitis.  Specific  pathogen-free 2-4-too-old fe- 
male  BALB/c or SJL/J mice were  obtained from the  National 
Cancer Institute (Bethesda, MD) and maintained in the Building 
10A Animal Facility at the National Institutes of Health. To in- 
duce  colitis,  the  mice were  lightly anesthetized  with metofane 
(methoxyflurane;  Pitman-Moore, Mundelein, IL). A 3.5F cathe- 
ter was then carefully inserted into the colon such that the tip was 
4 cm proximal to the anus. To induce colitis, 0.5 mg of the hap- 
ten reagent TNBS (Sigma Chemical Co., St. Louis, MO) in 50% 
ethanol (to break the intestinal epithelial barrier)  was slowly ad- 
ministered into the  lumen of the  colon via  the  catheter  fitted 
onto a l-ml syringe.  In control experiments, mice received 50% 
ethanol alone using the same technique described above. The to- 
tal injection volume was 100 ~1 in both groups  allowing TNBS 
or ethanol to reach  the entire colon, including the caecum and 
appendix.  Animals were then kept in a vertical position for 30 s 
and returned to their cages. 
Grading  of HistoIogic Changes.  Tissues were removed at indi- 
cated  time  points  and  embedded  in paraffin.  Paraffin  sections 
were made and stained with hematoxylin and eosin. The degree 
of inflammation on microscopic cross-sections  of the colon was 
graded  semiquantitatively from 0 to 4 (0, no signs of inflamma- 
tion; 1, very low level; and 2, low level ofleukocytic infiltration; 
3,  high  level  of leukocytic  infiltration, high  vascular  density, 
thickening of the  colon wall;  4,  transmural infiltrations,  loss of 
goblet cells, high vascular density,  thickening of the colon wall). 
Grading was done in a blinded fashion by the same pathologist. 
Morphometric  Assessment  of  Colon  Wall  Thickness.  Three  or 
more animals from each treatment group were randomly selected 
at the indicated time points (see Results),  and colon samples were 
removed and embedded in paraffin. Thickness of the colon wall 
was determined on cross-sections by measuring the distance from 
the serosal surface to the luminal surface at 2-ram intervals along 
the entire length of each section through a calibrated eyepiece us- 
ing a Vanox $1 microscope (Olympus Corp., Lake Success, NY). 
Immunohistochemistry.  Samples  were  put  into  OCT  com- 
pound on dry ice, and 7-I.Lm cryosections were cut according to 
standard  procedures.  Sections  were  then air  dried and fLxed in 
cold acetone for 2 rain at room temperature. Next, samples were 
rehydrated in PBS for 15 min, blocked with 5% FCS in PBS for 
20  rain,  and incubated with  FITC-conjugated rat  anti-mouse 
CD4 antibody (1:100  dilution; obtained from Pharmingen, San 
Diego, CA) for 45 rain in a dark humid chamber. Sections were 
then washed  for an additional 15  rain in PBS.  Finally, sections 
were mounted and analyzed with a fluorescence microscope  at an 
excitation wavelength of 490 nm. 
Quantification of CD4 +  T  lymphocytes was  performed  on 
cryostat sections for at least three specimens from each time point 
and each  treatment group  by examining 10  randomly selected 
high power fields  (HPFs).  Under our  experimental conditions 
(magnification of 400), one HPF represented 0.25 mm  2. 
Cell Isolation and Purification of LP CD4 + T  Cells.  LP lympho- 
cytes were isolated from freshly obtained colonic specimens using 
a modification of the technique described by van der Heijden and 
Stok  (17). After  removal of the Peyer's patches,  the colon was 
washed  in Ca/Mg-free HBSS,  cut into 0.5-cm pieces and incu- 
bated twice in HBSS containing EDTA (0.37 mg/rnl) and DTT 
(0.145 mg/ml) at 37~  for 15 min. Next, the tissue was digested 
further  in  RPMI  containing collagenase  D  (400  U/ml)  and 
DNase I (0.1 mg/ml) (Boehringer Mannheim Biochemicals,  In- 
dianapolis, IN) in a shaking incubator at 37~  LP cells were then 
layered  on  a  40-100%  Percoll  gradient  (Pharmacia,  Uppsala, 
Sweden),  and  lymphocyte-enriched populations  were  isolated 
from the cells at the 40-100% interface.  Enriched CD4  + T  cell 
populations were  obtained by  negative selection  using mouse 
CD4 + T  cell  isolation columns (IsoceLl; Pierce Chemical Co., 
Rockford, IL). The resultant cells when analyzed by flow cytom- 
etry (FACScan|  Becton Dickinson & Co., Mountain View, CA) 
contained >85% CD4 + ceils. 
Cell Culture of LP CD4 + T  Cells.  Cell cultures  ofLP CD4 + 
T cells were performed in complete medium consisting oflLPMI 
1640  (Whittaker Bioproducts,  Walkersville,  MD) supplemented 
with 3 mM t-glutamine, 10 mM Hepes buffer,  10 mg/ml genta- 
mycin (Whittaker),  100 U/ml each of penicillin  and streptomycin 
(Whittaker),  0.05  mM 2-ME  (Sigma Chemical Co.),  and  10% 
FCS. 
Reagents  and  mAbs.  Unconjugated and biotinylated mono- 
clonal rat anti-mouse IL-2 (clones JES6-1A12/JES6-5H4), IL-4 
(BVD4-1D11/BVD6-24G2),  IL-10  (JES5-2A5/SXC-1),  and 
IFN-'y (R4-6A2/XMG1.2) antibodies and mouse rlL-2 (specific 
activity =  2.5  ￿  106 BtLMP U/mg), IL-4 (107 U/rag by CTLL- 
2.4 assay), IL-10 (5  X  10  s U/mg), and IFN-'v (107 U/mg) were 
purchased from Pharmingen and Genzyme Corp.,  (Cambridge, 
MA),  respectively.  Purified  hamster  anti-mouse CD3~  (clone 
145-2Cll)  and hamster anti-mouse CD28  (clone 37.51)  anti- 
bodies were obtained from Pharmingen. 
Cytokine Assays.  To measure  cytokine production, 24-well 
plates (Costar Corp., Cambridge, MA) were coated with 10 I~g/ 
ml  murine anti-CD3e antibody in  carbonate  buffer  (pH  9.6) 
overnight at 4~  10  s LP CD4+ T cells were then cultured in 1 
ml of complete medium in precoated or uncoated wells, and I 
~g/ml soluble anti-CD28 antibody was added to the anti-CD3~- 
coated wells. Culture supematants were removed after 48 h and as- 
sayed for cytokine concentration. Cytokine concentrations were 
determined by specific ELISA per the manufacturer's recommen- 
dation (PharMingen) using Immulon 4 96-well microtiter plates 
(Dynatech Laboratories  Inc.,  Chantilly, VA).  ODs  were  mea- 
sured on a Dynatech MR 5000 ELISA reader at a wavelength of 
490 nm. 
Isolation  of Spleen  CD4 §  T  Cells.  Spleens were aseptically re- 
moved and subsequently digested  with collagenase  (400  U/ml) 
and DNase  I  (0.1 mg/ml) at  37~  for  15  min. After  filtration 
straining,  the  resulting splenocyte  suspension was  depleted  of 
RBC by hypotonic lysis with ACK lysing buffer (B & B Scott, 
W. Warwick, RI).  Cells  collected  from the 70-90% layer  of a 
Percoll gradient centrifugation underwent further negative selec- 
tion using mouse CD4  +  T  cell  isolation  columns as  described 
above.  As assessed by FACS  |  analysis, the resulting cell popula- 
tion contained >85% CD4 + cells. 
Cell Culture of Spleen  CD4 § T  Cells.  10  s spleen CD4+ T cells 
were cultured in 1 ml of complete medium (see above).  Culture 
supernatants  were removed after 48  h  and assayed for cytokine 
concentration as described above. 
In  Situ  Reverse  Transcriptase  PCR  (RT-PCR).  In  situ  RT- 
PCR for IFN-~ mRNA expression was performed as previously 
described  (18). Cryosections were placed  on charged  glass slides 
that were cut to fit into 0.5-ml Eppendorf tubes.  Samples were 
then fixed in 10% formaldehyde overnight at 4~  washed  three 
times in PBS and four times in autoclaved dH20 for 5 rain. Next, 
sections were permeabilized with 2 mg/ml trypsinogen (Sigma) 
in 0.01 N  HC1 for  15  rain at 25~  followed by neutralization 
with buffer A (0.1 M Tris HC1, pH 7.5, 0.1 M NaC1). For DNA 
degradation,  the sections were then incubated in RQ1  RNase- 
free DNase (8 U/100 ml; obtained from Promega Corp., Madi- 
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mM NaC1,  6 mM MgC12, and 0.1 mM CaC12 at 37~  for 12 min 
and at 75~  for 10 min. Next, sections were incubated for 60 rain 
at 50~  in a Perkin Elmer thermocycler in 100 ~1 of the follow- 
ing reaction mixture:  10  mM Tris HC1,  50  mM KC1,  1.5  mM 
MgCI:,  25  ~M  dATP,  25  p~M dTTP,  25  I-~M dCTP,  25  p~M 
dGTP  (Pharmacia Fine Chemicals, Piscataway, NJ),  100  nM  of 
either  IFN-',/  primer  (sense:  5'-GACAATCAGGCCATCAG- 
CAACAAC-3';  and  antisense  primer:  5'-TCCTGAGGCTG- 
GATTCCGGCAACA-3'  [19]),  10  mM  DTT,  75  U  ILNasin, 
400  U  M-MLV  reverse transcriptase  (GIBCO  BILL,  Gaithers- 
burg, MD). Slides were washed five times each in sodium citrate 
buffer (3 M NaC1, 0.3 M Na  3 citrate, pH 7.0, 2>< SSC), 1￿  SSC, 
0.5￿  SSC, and twice in dH:O. 
PCIL in situ of either sense- or antisense-primed cDNA was 
carried out in 100 ml of the following reaction mixture: 25  ~M 
of each  the  nucleotides  dATP,  dCTP,  dGTP,  and  23.7  ~M 
dTTP,  1.25  IxM digoxigenin-11-dUTP (dig-11-dUTP; obtained 
from Boehringer Mannheim),  10  mM  Tris-HC1,  50  mM KC1, 
1.5  mM MgC12, 5  U  Taq polymerase (Boehringer Mannheim), 
and 10 nM of IFN-',/primers. After denaturation of the samples 
for 4 rain at 95~  thermocycling was performed for five cycles 
(94~  70  s,  62~  1 min,  72~  1 min);  the final extension was 
done for 10 min at 72~  The samples were then washed in SSC 
solutions (2X SSC, 1X SSC, 0.5X  SCC; five times each) and im- 
munodetection was performed using the DIG nucleic acid detec- 
tion kit (Boehringer Mannheim). Next, sections were dehydrated 
in graded ethanols, placed in xylene, and mounted on coverslips. 
Treatment with Anti-IL-12  Antibodies.  The  hybridoma  cell 
line  (C17.8)  producing neutralizing rat anti-mouse  IL-12 anti- 
body was kindly donated by G. Trinchieri (The Wistar Institute, 
Philadelphia, PA [20, 21]). Ascites was prepared in nude mice ac- 
cording  to  standard  procedures,  and  antibodies  were  purified 
using E-Z-SEP purification kits (Middlesex Sciences, Inc., Fox- 
borough, MA). ILat control IgG was obtained from Jackson Im- 
munoResearch (West Grove, PA). 1 mg of rat anti-mouse IL-12 
antibodies or rat control IgG were administered intraperitoneally 
into mice pretreated with TNBS at indicated time points. 
Elispot Assay  for IFN-T.  10  s LP CD4 + T cells were incubated 
for 1 d in anti-CD3e-coated 24-well plates, and 1 p~g/ml soluble 
anti-CD28  antibody was  added.  Next,  cells  were  incubated in 
24-well  plates  that  were  coated  with  rat  anti-mouse  IFN-~/ 
(Pharmingen). After 12 h, plates were washed in PBS/Tween, bi- 
otinylated rat  anti-mouse  IFN-~/  (Pharmingen)  (2  ~g/ml)  was 
added,  and  incubation was  performed  overnight  at  4~  After 
washing  in  PBS/Tween  streptavidine-alkaline phosphatase  (1: 
1,000  dilution;  Zymed  Laboratories,  San  Francisco,  CA)  was 
added for 30  min  at  37~  Plates were  washed  again in  PBS/ 
Tween and the AP substrate (Promega Corp.) together with  1% 
agarose gel was added. Color reaction was allowed to proceed for 
24 h before spots were photographed. 
Results 
Intrarectal Administration  of TNBS Induces a Chronic Granu- 
Iomatous Colitis in BALB/c and SjL/j Mice.  Based on pre- 
vious studies showing that rectal administration of the hap- 
ten  reagent  TNBS  induces  colitis  in  rats  (22,  23),  we 
explored  the  possibility that  administration of TNBS  can 
induce  a  chronic  inflammation  of the  murine  colon.  We 
found that BALB/c and SJL/J mice subjected to intrarectal 
administration of TNBS  in  50%  ethanol reproducibly de- 
veloped pancolitis with severe diarrhea and rectal prolapse 
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(Fig. 1 a) accompanied by an extensive wasting disease (Fig. 
1  b).  The  peak  of clinical disease occurred  at  3  wk,  and 
clinical signs of colitis usually subsided after 2  mo.  Control 
mice  treated  with  50%  ethanol  alone  failed  to  develop 
wasting disease and appeared healthy. 
The colons ofTNBS-treated BALB/c mice removed 7 d 
after administration of TNBS  revealed striking hyperemia 
and  inflammation  (Fig.  2),  whereas  the  colons  of control 
mice  treated  with  50%  ethanol  alone  showed  no  macro- 
scopic  signs  of inflammation.  In  addition,  TNBS-treated 
mice displayed splenomegaly. 
Histologic analysis during the first days after induction of 
colitis showed infiltrations of neutrophil granulocytes into 
the  colon.  On  day 7,  a  transmural  inflammation affecting 
the  entire colon  (but sparing the  small bowel)  was  found. 
The  colitis was mainly characterized by lymphocytic infil- 
trates  that  were  associated  with  thickening  of the  colon 
wall,  ulcerations,  loss  of goblet  cells,  and  the  presence  of 
grannlomas (Fig. 3, a-b). 
Immunohistochemical  staining  showed  that  on  day  7, 
CD4+  T  cells were  increased in  colons of TNBS-treated 
mice  compared  to  control mice  (Fig.  3,  c-d).  The  differ- 
ences  in  inflammatory activity were  further  confirmed by 
histologic grading of the  colon  sections  (Table  1).  As  as- 
sessed  by  morphometric  analysis  of colon  wall  thickness 
and number of CD4 §  T  lymphocytes (Table 2), disease in- 
Figure  1.  Intrarectal administration of TNBS  induces severe diarrhea 
and wasting disease (a). Rectal prolapse ofa BALB/c mouse 7 d after ad- 
ministration of TNBS  in 50%  ethanol.  (b) Weight changes of normal 
BALB/c mice, control mice treated with 50% ethanol alone, and BALB/c 
mice  were  treated  with  TNBS  in  50%  ethanol  over  a  12-d  period. 
Weight data from one representative experiment is shown. Each point 
represents average weight data pooled from five mice. Standard errors are 
indicated.  ~,  Ethanol  group;  +,  normal BALB/c mice; 
TNBS-colitis group. Figure 2.  Macroscopic changes of colon and spleen in 
TNBS-treated mice. Photographs  of dissected large in- 
testine and spleen of a normal  BALB/c mouse  (top),  a 
control BALB/c mouse  treated with 50% ethanol  (sec- 
ond row), and two BALB/c mice treated with TNBS in 
50% ethanol  (bottom  rows) 7 d after the initial rectal ad- 
ministration. The colons of the TNBS-treated mice are 
severely inflamed, hyperemic,  and they contain less fe- 
ces due to massive diarrhea. 
tensity  usually peaked  between  2  and  4  wk  after  adminis- 
tration  of TNBS.  At later stages of the disease,  there was  a 
reduction  in  the  number  of granulocytes,  but  intramural 
lymphoid  aggregates  persisted  and  beginning  fibrosis  was 
found  (Fig.  3  e).  These  histological  signs  of inflammation 
were  still detected  up  to  2  mo  after TNBS  treatment,  but 
were absent in ethanol-treated  mice. 
Histologically, the spleens of TNBS-treated mice showed 
an increase in the size of the red pulp and the periarteriolar 
lymphoid  sheaths  on  day  7  when  compared  with  spleens 
from  control  mice  (Fig.  4,  a-b).  FACS  |  analysis  of spleen 
lymphocytes  revealed a  twofold increase  in the percentage 
of CD4 §  and  CD8 +  T  cells in  TNBS-treated  mice  com- 
pared  with  control  ethanol-treated  mice  and  normal 
BALB/c  mice,  along  with  a  reduction  in  B220 +  B  cells 
(data not shown). 
Figure 3.  Histologic analysis of the colon from 
BALB/c mice with TNBS-induced colitis and 
control mice. (a) Photomicrograph  of hematox- 
yhn and eosin-stained  paraffin section  of colon 
(￿  from a TNBS-treated BALB/c mouse 
on day 7. Loss of goblet cells and lymphocytic 
infiltrations are present.  (b) Photomicrograph  of 
hematoxylin  and eosin-stained  section of colon 
(￿  from a TNBS-treated mouse  on day 7 
showing  a granuloma.  (c)  Detection of CD4  + 
cells in the colon of a BALB/c mouse treated 
with TNBS on day 7 by immunofluorescence. 
FITC-positive cells were seen in the subepithe- 
lial areas and the lamina propria  (￿  100). (d) Immunostaining  with FITC-labeled anti-mouse CD4 antibodies in the colon of a control ethanol- 
treated BALB/c mouse on day 7. Only few positive cells were detected  (￿  100). (e) Photomicrograph  of hematoxyhn and eosin~tained section 
of colon (￿  150) from a TNBS-treated mouse after 7 wk showing chronic inflammation with intramural lymphoid aggregates and beginning  fi- 
brosis. 
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BALB/c Mice and from Mice with  TNBS-  induced Colitis Treated 
with Anti-IL-12,  Control Rat IgG, or with No Additional  Reagent 
Stimulated LP CD4 + T  Lymphocytes of TNBS-treated Mice 
Secrete  Thl  Cytokines.  To  examine  cytokine  production 
by  infiltrating  LP  CD4+T  cells  in  the  colon  of TNBS- 
treated mice, we purified this population from colonic tis- 
sue  specimens 7  d  after the  induction  of colitis and  com- 
pared their cytokine pattern with that of LP CD4 +  T  cells 
obtained from colonic tissue specimens of control ethanol- 
treated mice. Cells were cultured for 2 d  and culture super- 
natants  were  analyzed  for  concentration  of  Thl  (IL-2, 
IFN-y) and Th2  (IL-4, IL-10) cytokines by specific ELISA. 
As shown in Fig. 5  a, a  10-fold increase in the spontaneous 
Table 2.  Assessment  of Colon  Wall Thickness and Number of 
CD4 + T Lymphocytes per HPF in the Colon of TNBS- and 
Ethanol-treated BALB/c Mice at Dzfferent Time Points 
Colon wall thickness (~,m) 
CD4 + T lymphocytes 
per HPF 
Time 
point  Ethanol  TNBS  Ethanol  TNBS 
0 wk  226.4  +  12.5  210.4  +  20.8  3.7 +  0,4  3.7 +  0.4 
1 wk  239.8  +  6.0  419.8  +  38.9  5.1  -+ 0,5  38.9 -+ 4.1 
2 wk  213.0  -+ 8.5  522.2  +  76.2  4.7 --- 0,6  58.2 +  4.1 
4 wk  213.0  -+ 8.6  427.5  -+ 56.3  3.7 --- 0,4  76.1  +  6.4 
6 wk  219.3  +  16.0  394.2  +- 45.0  4.3 +  0,5  34.4 +  3.3 
8 wk  238.8  +  7.4  412.2  +  26.9  5.4 +  0.5  29.0 +  3.7 
Colon wall thickness is expressed in micrometers  +  SEM. The values 
for CD4 + T  lymphocytes reported are expressed as positive cells per 
HPF +  SEM. 
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Figure 4.  Histologic analysis of the  spleen from  mice  with  TNBS- 
induced colitis and control mice. Photomicrographs of hematoxylin and 
eosin--stained sections (￿  from spleens  of a control ethanol-treated 
BALB/c mouse (a) and a TNBS-treated  BALB/c mouse (b) on day 7. 
The spleen of the TNBS-treated mouse reveals hypervascularisation  and 
strikingly increased red pulp and periarteriolar lymphoid sheet areas. 
IFN-~/  production  of  LP  CD4 +  T  cells  was  found  in 
TNBS-treated mice.  Furthermore,  LP CD4 +  T  cells from 
TNBS-treated  mice  stimulated  with  anti-CD3  and  anti- 
CD28 produced 20-50-fold higher levels oflL-2 and IFN-~/ 
than  LP  CD4 §  T  cells  from  control  mice  (Fig.  5,  a-b). 
Similarily, an  increase  in  the  spontaneous  (4.5  vs  1.8  U) 
and induced (46 vs 16.8 U  after stimulation with anti-CD3 
and anti-CD28) IFN-~/production by spleen CD4 §  T  cells 
was found in the TNBS-treated animals compared with the 
ethanol control group at this time point. 
In contrast to the above finding, secretion oflL-4 by un- 
stimulated LP CD4 + T  cells from TNBS-treated mice was 
identical  compared  to  LP  CD4 +  T  cells  from  ethanol- 
treated control mice,  and in stimulated LP CD4+  T  cells 
from  TNBS-treated  mice,  the  average  secretion  of IL-4 
was reduced about fivefold compared with ethanol-treated 
control mice  (Fig.  5  c).  Finally, the  secretion of IL-10 by 
stimulated and unstimulated LP  CD4 +  T  cells was  similar 
in TNBS- and ethanol-treated n'rice (Fig. 5  d). 
In Situ  PCR Studies Show Elevated IFN-T mRNA  Expres- 
sion  in the  Colon of TNBS-treated  BALB/c Mice.  To deter- 
mine if the observed increase in IFN-y production was also 
observed at the mR.NA level, we evaluated the mRNA  ex- 
pression of IFN-~/ in the  colon of TNBS-treated mice by 
in situ PCP, studies. As shown in Fig. 6  a, control ethanol- 
treated animals did not show significant expression oflFN-y 
mR.NA on day 7.  In the TNBS-treated animals, however, 
we  found  a  dramatic  upregulation  of IFN-',/ mlLNA  ex- 
pression at the same time point (Fig. 6  b).  High staining in- 
tensity was seen particularly in the subepithelial areas. Figure 6.  Increased expression of IFN-y mRNA in the colon of BALB/c 
mice with  TNBS-induced  colitis.  (a)  In situ  PCR  staining for  IFN-~/ 
mRNA expression  in the colon of an ethanol-treated mouse.  Only very 
low staining intensity is found using antisense-primed cDNA as template 
for  the  PCR  reaction.  The  luminal site  (L)  of the  colon  is  indicated 
(￿  (b) In situ PCR staining for IFN-'y mRNA expression  in the co- 
lon of a TNBS-treated mouse.  High staining intensity is seen in the LP. 
The luminal site of the colon is indicated.  No staining was found with the 
antidigoxigenin antibody using sense-primed cDNA as template for the 
PCR reaction (data not shown) (￿  100). 
Figure  5.  Cytokine  production  of stimulated  and  unstimulated  LP 
CD4 + T  cells in TNBS-induced colitis. LP CD4 + T  cells were isolated 
from TNBS- and control ethanol-treated mice on day 7, cultured for 2 d 
in the absence or presence ofanti-CD3 and anti-CD28 (see Materials and 
Methods)  and culture supernatants  were  analyzed  for  concentration of 
IFN-'y (a), IL-2 (b), IL-4 (c), and IL-10 (d). Data represent three indepen- 
dent experiments done in triplicate.  Standard errors  are  indicated.  D, 
Ethanol group; II, TNBS-colitis group. 
Early Administration of Antibodies to IL-12 Represses Colitis 
and Abolishes  Wasting Disease in TNBS-treated Mice.  Since 
the  previous  data  suggested  the  presence  of activated  Thl 
cells  in  TNBS-induced  colitis,  we  sought  to  determine  if 
antibodies  to  IL-12  might  influence  disease  activity.  We 
therefore treated mice 5  and 9  d  after induction of the coli- 
tis systemically with anti-IL-12 or control rat IgG (see Ma- 
terials and Methods).  When  mice  were  treated with  anti- 
IL-12,  a  striking  improvement  of  the  wasting  disease 
became  apparent.  Anti-IL-12-treated  mice  became  more 
active  and  lost  their  ruffled  coat  appearance  when  corn- 
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Figure 7.  Anti-IL-12 antibodies abrogate colitis present 5 d after admin- 
istration  of TNBS.  (a) Weight changes of BALB/c mice with TNBS- 
induced cohtis after early administration (day 5) of anti-IL-12  antibodies 
or rat control  IgG. After initial reduction  of the body weight in both 
TNBS-treated groups, the mice treated with anti-IL-12 showed increase 
in the average body weight  after day 5, whereas mice treated with rat 
control IgG continuously lost body weight. Each point represents data 
from five mice.  The  standard errors are indicated. ~,  Anti-IL-12 
group; --0--, rat IgG control group. (b) Gross appearance of the colon 
from two TNBS-treated mice given anti-lL-12 antibodies (top rows) and 
two TNBS-treated mice given rat IgG (bottom rows) at day 12 after initial 
administration of TNBS. There was a reduction in inflammatory activity 
in the  anti-IL-12-treated mice.  One  representative experiment out of 
three is shown. 
pared with  untreated  mice  or mice given  control rat  IgG 
(data not shown);  in addition, as depicted in Fig. 7  a, mice 
that  had  received anti-IL-12  usually obtained  their initial 
body weight, whereas control IgG-treated mice continued 
to lose weight. Finally, gross inspection of the colon on day 
12  revealed reduction  in  inflammatory activity in  animals 
administered anti-IL-12 (Fig. 7  b). 
Histologic studies showed significantly less inflammatory 
cells in the colons of anti-IL-12-treated mice (Fig. 8  a-b). 
In most  cases,  anti-IL-12  treatment  completely abrogated 
the  TNBS-induced  inflammation  and  restored  a  normal 
histologic appearance of the colon. This was confirmed by 
histologic grading of colon sections: pooled data from three 
independent  experiments  showed  significant reduction  in 
inflammatory activity after anti-IL-12 treatment (Table 1). 
IFN-  T  Production  by Stimulated LP CD4  +  T  Cells  Is Re- 
duced  in  TNBS-treated Mice  Given Anti-IL-12.  Next,  we 
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Figure 8.  Histologic analysis  of the colon in mice with TNBS-induced 
colitis given anti-IL-12 or rat control IgG. (a) Photomicrograph of HE- 
stained cross section (￿  of a colon of a BALB/c mouse with TNBS- 
induced colitis after treatment with rat control IgG on day 12. There was 
a severe transmural cohtis. (b) Photomicrograph of HE-stained cross-sec- 
tion (X 100) of a colon of a BALB/c mouse with TNBS-induced cohtis 
after treatment with anti-IL-12 antibodies at the same time point. There 
was a striking reduction in the inflammatory activity of the colon. 
analyzed IFN-~ production by LP  CD4 +  T  cells in  anti- 
IL-12-treated animals. As shown in Fig. 9  a, we found an 
abrogation  of  high  level  IFN-y  production  in  TNBS- 
treated mice that had received anti-IL-12  compared with 
rat  IgG-treated mice  suggesting that  the  anti-IL-12 treat- 
ment might act by influencing the Thl-like response of lo- 
cal CD4 +  T  cells. In addition, Elispot assays for IFN-'y se- 
cretion by LP CD4 +  T  cells showed a  dramatic reduction 
in the average number of Elispots in the anti-IL-12-treated 
group compared to the rat control IgG-treated group  (Fig. 
9  b-c).  The  size  of the  Elispots,  however,  was  similar in 
both groups, indicating that the reduction in IFN-~/secre- 
tion by LP CD4+  T  cells from anti-IL-12-treated mice is 
mainly due to a reduction in the number of IFN-'y-secret- 
ing cells. 
Late Administration of  Antibodies to IL-12 Abolishes Wasting 
Disease  in  Mice  with  TNBS-induced  Colitis.  Finally,  we 
wanted to determine if anti-IL-12 treatment would be ef- 
fective during later phases  of the  disease when  colitis was 
fully established. We thus started administration ofanti-IL-12 
or control rat IgG on day 20  and repeated such  treatment 
on  days 24  and  28.  As shown  in  Fig.  10  a,  a  striking in- 
crease in the average weight of mice was found after anti- 
IL-12  treatment  but  not  after  rat  control  IgG  treatment. 
Furthermore, when LP CD4 + T  cells from such mice were 
stimulated with anti-CD3  and anti-CD28,  we found a  re- 
duction of IFN-~ secretion in those mice given anti-IL-12, 
but not those given rat control IgG (Fig. 10 b). Figure 9.  Analysis of IFN-3~ production in BALB/c mice with TNBS- 
induced  colitis given anti-IL-12 or rat control IgG. (a) Cytokine produc- 
tion of LP CD4 + T  cells from TNBS-treated animals on day 12. There 
was an abrogation of high-level IFN-'y secretion in the anti-IL-12-treated 
animals, l,  Rat IgG control group;  i~, anti-IL-12 group.  (b) Ehspot as- 
say for IFN-~/ secretion.  LP CD4  + T  lymphocytes  from TNBS-treated 
mice given rat control IgG were isolated and analyzed as specified in Ma- 
terials and Methods.  A high number of Elispots per high power field was 
seen.  (c) Elispot assay for IFN-~/ secretion  using LP CD4 + T  cells from 
anti-IL-12-treated mice. There was a striking reduction in the average 
number of  Elispots per high power field in the mice treated with anti-IL- 
12 antibodies compared with those given control IgG. 
Discussion 
In the present  study,  we describe  a  novel routine  model 
of chronic intestinal  inflammation induced by a  single rec- 
tal  administration  of the  hapten  reagent  TNBS.  Further- 
more,  we  demonstrate  that  the  inflammation  is  associated 
with  a  Thl  T  cell response  and  can  be  abrogated  by  sys- 
temic  treatment  with  antibodies  against  IL-12,  even  after 
inflammation is well established. 
The  immune  responses  to  hapten  determinants  such  as 
TNBS  are believed to  depend  on the haptenization  of au- 
tologous proteins  and presentation  of MHC  class  II-fitting 
peptides  to  CD4 +  T  cells by antigen  presenting  cells,  ulti- 
mately leading to specific CD4 §  T  cell recognition,  T  cell 
expansion,  and  T  cell cytokine  responses  (24).  While hap- 
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reactions, the hapten-induced responses in the colon mani- 
fest a striking chronicity,  as shown by the fact that histo- 
logic signs of inflammation were still present 2 mo after the 
mice were initially treated with TNBS.  A  similar chronic 
colonic inflammation for at least 2 mo after rectal adminis- 
tration of TNBS in rats has been described (22). 
The murine  TNBS model of chronic  intestinal  inflam- 
mation  contains  several  features  that  distinguish  it  from 
previously described models (4-8):  First, the inflammation 
is rapidly and reliably induced  in  a mouse with  a  normal 
immune system so that it does not require the loss of a ma- 
jor  immune  capacity.  Second,  and  perhaps  most  impor- 
tantly, a chronic colitis is induced that is characterized by a 
severe,  transmural  inflammation  associated  with  diarrhea, 
rectal prolapse,  and weight loss.  These  clinical  and histo- 
pathological features underscore that TNBS-induced colitis 
mimics some important  characteristics  of CD  in  humans. 
As  such,  the  formation  of granuloma  in  TNBS-induced 
colitis is interesting since  granuloma can also  be found in 
CD  in  humans  (25)  and  granulomatous  inflammation  is 
considered the most specific histological finding in this dis- 
ease (26). 
Analysis of cytokine production by stimulated LP CD4 + 
T  cells  derived  from  mice  with  TNBS-induced  colitis 
showed strikingly elevated levels of IL-2 and IFN-~ pro- 
duction.  This Thl  pattern of cytokine response resembles 
that obtained in  hapten-induced  delayed type hypersensi- 
tivity in the skin (27,  28).  Since recent studies of cytokine 
patterns from intestinal T  cells in IBD have shown a higher 
number of IL-2- and IFN-~/-secreting cells,  as well as in- 
creased IFN-y mRNA and protein levels in patients with 
CD  (reference 29  and Fuss  I., M.  F.  Neurath,  M.  Boivi- 
vant, C. Fiocchi, I. S. Klein, S. A. Strong, and W. Strober, 
manuscript in preparation), the cytokine pattern of T  cells 
in the murine TNBS-induced colitis is consistent with that 
found in CD.  Furthermore,  the levels of IL-4 secreted by 
stimulated  LP  CD4 +  T  cells  were  normal  or  reduced  in 
TNBS-treated mice resembling the normal or reduced lev- 
els secreted by stimulated LP CD4 + T  cells in CD (Fuss et 
al.,  manuscript in preparation). Thus, TNBS-induced coli- 
tis in mice has some similarity to human CD at the T  cell 
cytokine level. 
Perhaps one of the most striking aspects of the findings 
reported here is that the TNBS-induced colitis can be suc- 
cessfully treated  with  antibodies  against  IL-12,  even after 
the lesion is established. Thus, when we administered anti- 
IL-12  to  mice  5  d  after TNBS  administration,  at  a  time 
when  they were already losing weight  and showing  clear 
evidence ofmucosal inflammation, we found an abrogation 
of the TNBS-induced wasting disease with a dramatic re- 
duction of the macroscopic and histologic signs  of inflam- 
matory  activity.  Similarly,  TNBS-induced  colitis  present 
20 d after TNBS exposure was also repressed by anti-IL-12 
administration.  This finding  suggests  that  the  presence  of 
IL-12 is essential to maintain TNBS-induced colitis and a 
persistent local Thl cytokine response. Therefore, the most 
likely mechanism by which  anti-IL-12 influences TNBS- 
induced colitis is the prevention of a Thl-like response of 
intestinal LP T  lymphocytes. This hypothesis is supported 
by the  finding  that  stimulated  LP  CD4 +  T  cells  isolated 
from mice with  TNBS-induced  colitis  after early  or late 
administration  of anti-IL-12 failed to produce high levels 
of IFN-y. That this effect is at least caused by changes in 
the  transcriptional  regulation  of the  IFN-~/  promoter  is 
supported by electrophoretic mobility shift studies showing 
that anti-IL-12 causes a striking reduction of inducible nu- 
clear complexes that  bind  to  regulatory sequences  of the 
IFN-~/promoter (Neurath, M. F., I. Fuss,  and W. Strober, 
unpublished data). 
The central importance of the pluripotent cytokine IFN-y 
in  transmural  granulomatous  colitis  has  been  recently 
shown by an elegant series of experiments by Powrie et al. 
(8) in which it was found that the colitis induced in C.B.- 
17  scid mice by adoptive transfer of CD45RB hi  T  cells  is 
associated with a Thl-T  cell response and responds to sys- 
temic  treatment with  anti-IFN-~.  Similarly, we have re- 
cently found that antibodies to IFN-y partially reverse es- 
tablished TNBS-induced colitis in mice (Neurath, M. F., I. 
Fuss,  and  W.  Strober,  unpublished  data).  Perhaps  even 
more strikingly, we found in preliminary studies in the mu- 
rine TNBS-induced colitis model that no significant chronic 
colitis could be induced in BALB/c mice in which the gene 
for IFN-',/is inactivated by homologous recombination. One 
may speculate that IFN-y functions in experimental colitis 
via its ability to induce cellular migration into tissues through 
its  effect on the  expression  of several adhesion  molecules 
(reviewed in 30). Furthermore, it is a key activator ofmac- 
rophages; in this regard, IFN-~/might influence experimen- 
tal colitis by facilitating macrophage secretion of inflamma- 
tory cytokines. 
In summary, the data demonstrate the pivotal role of IL- 
12 and IFN-3, in a murine Thl model of chronic intestinal 
inflammation induced  by the  hapten  reagent TNBS.  The 
fact that this inflammation is abrogated by anti-IL-12 treat- 
ment, together with its similarity to CD, suggests that anti- 
IL-12  antibodies  have potential  therapeutic  utility  in  pa- 
tients with this disease.  This hypothesis is supported by the 
recent finding (unpublished data) that there is a striking in- 
crease in  IL-12 p35/p40  (p70)  heterodimer expression,  as 
assessed by immunohistochemistry, in the colon of patients 
with CD compared to normal colon. 
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